FOURTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND SECOND AMENDMENT TO DISCLOSURE LETTERNote Purchase Agreement • March 2nd, 2023 • Puma Biotechnology, Inc. • Pharmaceutical preparations
This FOURTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND SECOND AMENDMENT TO DISCLOSURE LETTER (the “Agreement”) dated as of November 29, 2022 is entered into by and among PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party hereto and ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, as the Administrative Agent. All capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Note Purchase Agreement (as defined below).
SECOND AMENDMENT TO NOTE PURCHASE AGREEMENTNote Purchase Agreement • March 2nd, 2023 • Puma Biotechnology, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO NOTE PURCHASE AGREEMENT (the “Agreement”) dated as of May 18, 2022 is entered into by and among PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party hereto and ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, as the Administrative Agent. All capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Note Purchase Agreement (as defined below).
